Delcath Systems, Inc. (NASDAQ:DCTH) Receives Consensus Recommendation of “Hold” from Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has been given a consensus rating of “Hold” by the seven brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $22.50.

Several equities research analysts have recently commented on the company. Evercore set a $27.00 price target on Delcath Systems in a research note on Thursday, February 26th. Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. BTIG Research cut their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Zacks Research cut Delcath Systems from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Finally, Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently modified their holdings of DCTH. Nantahala Capital Management LLC purchased a new stake in shares of Delcath Systems during the third quarter worth approximately $7,164,000. Marshall Wace LLP purchased a new stake in shares of Delcath Systems during the second quarter worth approximately $6,572,000. Divisadero Street Capital Management LP purchased a new stake in shares of Delcath Systems during the third quarter worth approximately $5,119,000. Rosalind Advisors Inc. raised its stake in shares of Delcath Systems by 13.8% during the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock worth $44,885,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Delcath Systems by 116.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock worth $5,936,000 after purchasing an additional 315,583 shares during the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Down 3.4%

DCTH stock opened at $11.07 on Friday. The company has a market capitalization of $382.14 million, a P/E ratio of 1,107.00 and a beta of 0.54. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $18.23. The business has a 50 day simple moving average of $10.13 and a 200-day simple moving average of $9.85.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.07. The business had revenue of $24.99 million during the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. Research analysts predict that Delcath Systems will post -0.88 EPS for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.